What is the USP 800 hazardous drug list, and how do recent changes affect your pharmacy’s compliance requirements?
The December 2024 NIOSH update fundamentally changed how pharmacies classify and handle hazardous drugs. [1] The NIOSH List of Hazardous Drugs in Healthcare Settings now uses two tables instead of three, adds 25 drugs, and removes seven others.
For pharmacy directors managing sterile compounding operations, these changes require immediate action:
- Review assessment of risk documentation
- Update handling protocols for reclassified drugs
- Revise staff training materials
This guide covers the new two-table classification system, handling requirements based on drug classification, and evaluation processes for newly approved drugs not yet NIOSH-reviewed.
What is the USP 800 Hazardous Drug List?
The USP 800 hazardous drug list refers to the NIOSH List of Hazardous Drugs in Healthcare Settings, which identifies drugs that pose occupational safety risks to healthcare workers. USP General Chapter 800 references this NIOSH list to establish handling requirements for hazardous drugs in all healthcare settings.
Key facts about the list:
- Published by NIOSH (National Institute for Occupational Safety and Health), not USP
- Updated in December 2024 with 25 drugs added and 7 removed
- Now organized into 2 tables (reduced from 3 in 2016 version)
- Includes drugs with carcinogenic, reproductive, developmental, or genotoxic properties
- Healthcare facilities must reference this list for USP 800 compliance
How to Interpret NIOSH Table 1 and 2 Classifications
The December 2024 NIOSH update restructured hazardous drug classifications in ways that affect handling protocols, assessment of risk documentation, and staff training. Pharmacies using the 2016 list will encounter significant changes, particularly the elimination of Table 3 and reorganization of Table 1.
Important Note: The following describes the NIOSH list structure referenced by USP 800. Actual containment requirements are determined by USP 800 Box 1, which focuses on whether drugs are antineoplastic and require manipulation.
Understanding the December 2024 Table Restructuring
NIOSH consolidated the three-table system into two tables, fundamentally changing how you classify drugs. Table 3, which previously identified drugs with reproductive hazards, no longer exists. Those drugs were redistributed to Table 2 based on their hazard profiles.
The update also moved 35 drugs from Table 1 to Table 2, and NIOSH removed “antineoplastic” as the Table 1 descriptor. This matters because not all Table 1 drugs are cancer treatments, and some cancer treatments now appear in Table 2.
If your protocols referenced “Table 3 drugs” or assumed “all Table 1 equals antineoplastic,” those standard operating procedures need immediate revision. Accreditation surveyors will compare your documentation against the current 2024 list, not the outdated 2016 version.
Table 1 Classification Criteria
Drugs qualify for Table 1 if they meet ONE of these criteria:
Option 1: Manufacturer’s Special Handling Information (MSHI)
- Package insert includes specific warnings about handling precautions for healthcare workers
Option 2: High-Level Carcinogen Classification
- Meets NIOSH hazardous drug definition AND classified by:
- National Toxicology Program (NTP): “known to be a human carcinogen”
- International Agency for Research on Cancer (IARC): Group 1 “carcinogenic to humans” or Group 2A “probably carcinogenic to humans”
Compliance Impact: Table 1 drugs requiring manipulation beyond counting or repackaging must follow ALL USP 800 containment requirements: negative pressure storage, containment primary engineering controls (C-PEC), supplemental engineering controls, and full personal protective equipment. No exceptions through assessment of risk for Table 1 antineoplastic drugs.
Table 2 Classification Criteria
Table 2 includes drugs that meet one or more NIOSH hazardous drug criteria but don’t qualify for Table 1. Specifically, Table 2 drugs:
- Meet one or more NIOSH hazardous drug criteria (carcinogenicity, teratogenicity, developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity)
- Do NOT have manufacturer’s special handling information
- NOT classified by NTP as known human carcinogen
- NOT classified by IARC as Group 1 or 2A
Assessment of Risk Opportunity: Table 2 drugs are eligible for assessment of risk. You can evaluate dosage form, route of administration, and manipulation requirements to determine if alternative containment strategies apply. This flexibility doesn’t mean Table 2 drugs are “safe”—many have reproductive or developmental hazards—but handling protocols may be adjusted based on documented risk assessment.
Important Note: Former Table 3 drugs (primarily reproductive hazards) are now in Table 2. Review your assessment of risk documentation if you previously applied special protocols for reproductive-risk drugs.
Handling Requirements Based on Drug Classification
Understanding which table a drug appears on directly determines your containment requirements, personal protective equipment protocols, and engineering control specifications. While USP 800 establishes baseline standards for all hazardous drugs, Table 1 drugs requiring manipulation demand the most rigorous controls.
Table 1 Handling Requirements (Full Containment)
When Table 1 drugs require manipulation (anything beyond counting intact oral solids or repackaging):
Storage Requirements:
- Negative pressure storage areas
- Segregated from non-hazardous inventory
- Proper ventilation with dedicated HVAC
Compounding Requirements:
- Containment primary engineering control (C-PEC): Class II or III biological safety cabinet or compounding aseptic containment isolator (CACI)
- Negative pressure buffer room for sterile compounding
- Properly ventilated room for non-sterile compounding
- Supplemental engineering controls when appropriate
Personal Protective Equipment:
- Double chemotherapy gloves (outer pair sterile for sterile compounding)
- Chemotherapy gown meeting ASTM standards
- Hair covers, beard covers, shoe covers for sterile preparations
- Face shield or goggles when splash risk exists
Table 1 antineoplastic drugs cannot use assessment of risk to reduce these requirements.
Need help implementing monthly surface sampling or six-month cleanroom certification? Allometrics specializes in pharmacy-specific USP 797/800 compliance programs. Call (281) 474-3329 for flexible scheduling that works around your compounding operations.
Table 2 Handling Requirements (Risk-Based Approach)
Assessment of risk flexibility defines Table 2 handling protocols. You can document risk assessments considering:
- Final dosage form (intact tablets versus solutions)
- Manipulation required (counting versus crushing versus compounding)
- Route of administration
- Frequency and quantity handled
Common Risk Scenarios:
Lower risk situations include dispensing manufacturer-sealed tablets or capsules without manipulation. These may require minimal containment beyond standard pharmacy practices.
Higher risk situations involve crushing tablets (generates dust), compounding liquid preparations (aerosolization potential), or reconstituting injectables. These require more rigorous containment approaches similar to Table 1 protocols.
Every assessment of risk must be documented, reviewed annually, and available during accreditation surveys. [2] Joint Commission and state boards expect written justification for any deviation from full containment protocols. [3] Missing documentation creates immediate survey findings.
Environmental Monitoring Requirements
Regardless of table classification, USP 800 mandates environmental monitoring for all hazardous drug handling areas.
Routine environmental monitoring is required in compounding areas, storage areas, and adjacent spaces to detect hazardous drug contamination. USP 800 mandates surface sampling at least every six months, with documentation of results and trending data. Many pharmacies choose more frequent sampling schedules to maintain tighter control over environmental quality.
Accreditation surveyors examine environmental monitoring records closely. Gaps in required sampling or lack of corrective action documentation are common citations. Your environmental monitoring program must demonstrate consistent compliance, not sporadic testing when convenient.
Self-collection programs provide added benefit of staff education—when personnel perform their own sampling, they develop stronger awareness of contamination sources and proper cleaning protocols.
Process for Evaluating New Drugs Not Yet on NIOSH List
The 2024 NIOSH list only includes drugs approved through December 2015, with select additions through May 2023. This creates a significant gap—hundreds of drugs approved between 2016 and 2025 haven’t been evaluated. Healthcare facilities remain responsible for identifying and handling these unlisted hazardous drugs.
When to Conduct Independent Hazard Assessment
Your pharmacy must evaluate drugs not on the NIOSH list when:
- New drug approvals enter your formulary
- FDA adds black box warnings to existing drugs
- Manufacturer updates package insert with safety warnings
- Drugs exhibit structural similarity to known hazardous drugs
Recent example: In November 2024, IARC added hydrochlorothiazide to Group 1 “carcinogenic to humans,” requiring pharmacy evaluation despite not appearing on the current NIOSH list.
Step-by-Step Evaluation Process
Step 1: Review Package Insert for MSHI
If the manufacturer includes special handling information, the drug automatically qualifies as hazardous. Add it to your facility list immediately with Table 1 classification.
Step 2: Check NTP and IARC Classifications
Review the National Toxicology Program database and IARC Monographs for carcinogen classification. Drugs classified as known or probable human carcinogens qualify for Table 1.
Step 3: Evaluate NIOSH Hazard Criteria
Does the drug demonstrate carcinogenicity, teratogenicity, developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structural similarity to listed hazardous drugs? Drugs meeting any criteria without MSHI or high-level carcinogen classification belong in Table 2.
Step 4: Document Decision
Create written assessment including references, criteria evaluated, and handling determination. Store with USP 800 compliance documentation for surveyor review.
Maintaining Your Facility-Specific List
USP 800 requires annual review of your hazardous drug list. Best practice suggests quarterly reviews when new drugs enter formulary, NIOSH publishes updates, FDA issues safety communications, or IARC/NTP updates classifications.
Assign responsibility to a designated person (typically pharmacy director or quality manager) for monitoring FDA approvals, safety alerts, and maintaining documented evaluation records. This proactive approach prevents survey findings and protects worker safety.
Your facility-specific list should include all NIOSH-listed drugs you handle plus any unlisted drugs you’ve evaluated as hazardous. Surveyors will review both your list and your evaluation documentation during inspections.
Protect Your Staff and Pass Your Next Survey
The December 2024 NIOSH update requires immediate review of your assessment of risk documentation and handling protocols. Pharmacy directors face three compliance requirements: accurate drug classification using the current two-table system, proper implementation of handling requirements, and documented evaluation for unlisted drugs.
Environmental monitoring creates the biggest challenge for most pharmacies. Routine surface sampling, six-month cleanroom certifications, and gloved fingertip sampling all require coordination around patient care schedules.
Allometrics provides USP 797/800 cleanroom certification with ISO 17025 accredited instruments. Our technicians understand healthcare scheduling constraints and provide flexible testing that works around chemotherapy preparation and critical medication compounding.
Call (281) 474-3329 to schedule your cleanroom certification or discuss cost-effective monthly sampling programs that meet USP requirements without breaking your budget.
